Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.84B | $2.07B | $2.34B | $2.61B | $2.96B | $3.20B | $3.58B | $4.22B | $4.69B | $5.15B |
| Revenue growth | — | 12.4% | 13.2% | 11.4% | 13.4% | 8.1% | 11.9% | 18.0% | 10.9% | 9.8% |
| Gross profit | $1.07B | $1.20B | $1.33B | $1.49B | $1.72B | $1.84B | $2.02B | $2.36B | $2.66B | $3.05B |
| Gross margin | 58.0% | 58.1% | 57.0% | 57.3% | 58.1% | 57.5% | 56.6% | 55.8% | 56.7% | 59.4% |
| Operating income | $429M | $426M | $542M | $579M | $810M | $904M | $1.00B | $1.13B | $1.32B | $1.69B |
| Operating margin | 23.3% | 20.6% | 23.2% | 22.2% | 27.4% | 28.3% | 28.0% | 26.8% | 28.2% | 32.7% |
| Net income | $352M | $342M | $316M | $405M | $622M | $475M | $779M | $898M | $1.02B | $1.40B |
| Net margin | 19.2% | 16.6% | 13.5% | 15.5% | 21.0% | 14.8% | 21.8% | 21.3% | 21.8% | 27.2% |
| EPS (diluted) | $2.49 | $2.40 | $2.19 | $2.80 | $4.27 | $3.24 | $5.30 | $6.09 | $6.92 | $9.51 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $548M | $414M | $505M | $459M | $802M | $737M | $351M | $693M | $1.40B | $1.75B |
| Capital expenditures | $58.5M | $62.2M | $62.6M | $68.7M | $95.3M | $103M | $135M | $120M | $99.5M | $89.9M |
| Free cash flow | $489M | $352M | $442M | $390M | $707M | $634M | $216M | $574M | $1.30B | $1.66B |
| Share buybacks | $102M | — | $53.8M | $22.8M | — | — | $0.00 | $0.00 | $150M | $300M |
| Dividends paid | $168M | $186M | $199M | $212M | $225M | $227M | $245M | $258M | $282M | $311M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $731M | $822M | $189M | $147M | $463M | $295M | $274M | $228M | $238M | $1.21B |
| Total assets | $3.26B | $3.47B | $3.06B | $4.11B | $4.59B | $4.73B | $5.10B | $6.75B | $6.87B | $8.17B |
| Total liabilities | $1.56B | $1.51B | $1.00B | $2.04B | $2.09B | $1.84B | $1.74B | $2.62B | $2.01B | $2.21B |
| Long-term debt | $873M | $1.08B | $270M | $1.26B | $1.16B | $643M | $765M | $1.43B | $697M | $658M |
| Shareholders' equity | $1.69B | $1.96B | $2.06B | $2.07B | $2.50B | $2.89B | $3.36B | $4.13B | $4.86B | $5.97B |
| Retained earnings | $2.16B | $2.32B | $2.43B | $2.44B | $2.83B | $3.08B | $3.61B | $4.25B | $4.99B | $6.08B |
| Shares (wtd avg diluted) | 142M | 142M | 144M | 144M | 146M | 146M | 147M | 147M | 148M | 147M |
Every figure is extracted from RESMED INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.